PainWeek_logo.png

September 11-13, 2020

CONFERENCE POSTERS

RESUME_1_Logo.png
RESUME_2_Logo.png

Poster #65: Tolperisone 100 and 200 mg Three Times Daily (TID) for Acute Muscle Spasm of the Back: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase 3 Study

Authors:

 

Randall Kaye, MD; Henry Riordan, PhD; Srinivas Nalamachu, MD; Joseph Pergolizzi, MD; Sanam Ara Vaughan

Key Highlights: Approximately 750 subjects are planned to be enrolled at about 60 clinical sites in the United States, with the first subject expected to be enrolled in Fall 2020. A second replicate Phase 3 study will be initiated at a later date.

StarStudy_logo.png

Poster #75: Tolperisone for Acute Muscle Spasm: Dose-Ranging STAR Study

Authors:

 

Srinivas Nalamachu, MD; Randall Kaye, MD; Joseph Pergolizzi, MD

 

Key Highlights: Tolperisone dose of 200 mg TID may be a promising treatment for the management of acute muscle spasm without the somnolence typically experienced with skeletal muscle relaxants.

OTHER POSTERS & PUBLICATIONS

Publication: Driving Study

 

An assessment of the centrally acting muscle relaxant tolperisone on driving ability and cognitive effects compared to placebo and cyclobenzaprine

Authors:

 

Judy Caron PhD; Randall Kaye MD; Thomas Wessel MD, PhD; Amy Halseth PhD; Gary Kay PhD

 

What is new and conclusion: Subjects who received tolperisone (150 mg TID) experienced no impact on various measures of driving, self-reported sleepiness and cognition measures compared to placebo, in contrast to those who received the widely used muscle relaxant cyclobenzaprine (10 mg TID)

medpage-today_LOGO.jpg

Publication: MEDPAGE TODAY

 

Novel Form of Muscle Relaxant Shows Benefit
— Tolperisone may help pain from acute back spasms without causing drowsiness

Authors:

 

Judy George, Senior Staff Writer, MedPage Today September 5, 2020

 

Key Highlights:  Tolperisone, a centrally-acting muscle relaxant, may treat symptoms of acute muscle spasms without the sleepiness and cognitive effects associated with other skeletal muscle relaxants, data from the phase II STAR trial suggested.